MedTrace Logo

Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection

NCT00128271 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2008-05-07

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis C virus in individuals with chronic infection.

Conditions

  • Hepatitis C

Interventions

DRUG

Bavituximab

Sponsors & Collaborators

  • Peregrine Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Eliot W Godofsky, MD, FACP · Bach & Godofsky, MD, PA

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00128271 on ClinicalTrials.gov